Assessment of Adult Women With Ovarian Masses and Treatment of Epithelial Ovarian Cancer: ASCO Resource-Stratified Guideline

Verna D. Vanderpuye, MD; Jean Rene V. Clemenceau, MD; Sarah Temin, MSPH; Zeba Aziz, MD; William M. Burke, MD; Nixon Leonardo Cevallos, MD; Linus T. Chuang, MD; Terence J. Colgan, MD; Marcela G. del Carmen, MD; Keiichi Fujiwara, MD, PhD; Elise C. Kohn, MD; Jose Enrique González-Nogales, MD; Thomas Okpoti Konney, MD; Asima Mukhopadhyay, MD, PhD, MSc; Bishnu D. Paudel, MD; Icsó Tóth; Sarikapan Wilailak, MD; and Rahel G. Ghebre, MD, MPH

PURPOSE To provide expert guidance to clinicians and policymakers in three resource-constrained settings on diagnosis and staging of adult women with ovarian masses and treatment of patients with epithelial ovarian cancer (including fallopian tube and primary peritoneal) cancer.

METHODS A multidisciplinary, multinational ASCO Expert Panel reviewed existing guidelines, conducted a modified ADAPTE process, and conducted a formal consensus process with additional experts.

RESULTS Existing sets of guidelines from eight guideline developers were found and reviewed for resource-constrained settings; adapted recommendations from nine guidelines form the evidence base, informing two rounds of formal consensus; and all recommendations received ≥ 75% agreement.

RECOMMENDATIONS Evaluation of adult symptomatic women in all settings includes symptom assessment, family history, and ultrasound and cancer antigen 125 serum tumor marker levels where feasible. In limited and enhanced settings, additional imaging may be requested. Diagnosis, staging, and/or treatment involves surgery. Presurgical workup of every suspected ovarian cancer requires a metastatic workup. Only trained clinicians with logistical support should perform surgical staging; treatment requires histologic confirmation; surgical goal is staging disease and performing complete cytoreduction to no gross residual disease. In first-line therapy, platinum-based chemotherapy is recommended; in advanced stages, patients may receive neoadjuvant chemotherapy. After neoadjuvant chemotherapy, all patients should be evaluated for interval debulking surgery. Targeted therapy is not recommended in basic or limited settings. Specialized interventions are resource-dependent, for example, laparoscopy, fertility-sparing surgery, genetic testing, and targeted therapy. Multidisciplinary cancer care and palliative care should be offered.

Additional information can be found at www.asco.org/resource-stratified-guidelines. It is ASCO’s view that health care providers and health care system decision makers should be guided by the recommendations for the highest stratum of resources available. The guideline is intended to complement but not replace local guidelines.

INTRODUCTION The purpose of this guideline is to provide expert guidance on the diagnosis and treatment of adult women 18 years of age or older with epithelial ovarian cancer (EOC) (including fallopian tube and primary peritoneal cancer) to clinicians, public health leaders, patients, and policymakers in resource-constrained settings. The target population is adult women with ovarian masses and other symptoms of ovarian cancer as well as those diagnosed with EOC at all stages in resource-constrained settings. The guideline is not intended for patients in maximal or enhanced settings, as described in Table 3.

Ovarian cancer is often diagnosed at an advanced stage, stage III or IV. All women are at risk for ovarian cancer; women with genetic predisposition; personal or family history of breast, ovarian, or colon cancer; infertility; and advancing age are at higher than population-based risk. There is currently no reliable screening method or primary prevention available for ovarian cancer in any setting. Therefore, most women with ovarian cancer are diagnosed on the basis of symptomatic presentation with the majority at advanced stages across all resource settings. In basic settings, chest x-ray and abdominal ultrasound are typically the only imaging modalities available. Women with ovarian cancer report nonspecific symptoms that may be overlooked or misdiagnosed by primary care providers and contribute to delay in diagnosis. In resource-constrained settings, patients with advanced
THE BOTTOM LINE

Assessment of Adult Women With Ovarian Masses and Treatment of Epithelial Ovarian Cancer: ASCO Resource-Stratified Guideline

Key Questions

For each of the three resource-constrained settings levels (basic, limited, and enhanced):

(A) What are the optimal diagnosis and staging strategies for adult women with ovarian masses and/or EOC (including fallopian tube and primary peritoneal cancer)?

(B) What is the optimal surgery for women with stages I-IV EOC (including fallopian tube and primary peritoneal cancer)?

(C) What is the optimal adjuvant and/or systemic therapy for stages I-IV EOC (including fallopian tube and primary peritoneal cancer)?

(D) What is the optimal therapy for women with recurrent EOC (including fallopian tube and primary peritoneal cancer)?

Target Population

Adult women (18 years of age or older) in three resource-constrained settings levels with ovarian masses and/or diagnosed with EOC (including fallopian tube and primary peritoneal cancer)?

Target Audience

This guideline globally targets health care providers (including gynecologic oncologists, medical oncologists, radiation oncologists, obstetricians and gynecologists, surgeons, nurses, and palliative care clinicians) and nonmedical community members, including patients, caregivers, and member(s) of advocacy groups.

Methods

A multinational, multidisciplinary Expert Panel was convened to develop clinical practice guideline recommendations on the basis of a systematic review of the medical literature and an expert consensus process.

Author’s note: It is the view of the ASCO that health care providers and health care system decision makers should be guided by the recommendations for the highest stratum of resources available. The guidelines are intended to complement but not replace local guidelines. General statement about recommendations: referral to higher-resource level settings, if feasible, is preferable.

Key Recommendations—Because of the Large Number of Recommendations, Only a Summary of Key Recommendations Are in This Box

Clinical question A.

What are the optimal diagnostic strategies for adult women with ovarian masses and/or symptoms of EOC (including fallopian tube and primary peritoneal cancer)?

- General practitioners should perform a clinical assessment and family history and where available, aid diagnosis by ultrasound (abdominal and transvaginal ultrasound, Doppler-enhanced) AND/OR contrast-enhanced computed tomography (CT) of abdomen and pelvis (with or without thorax).
- In postmenopausal women with symptoms of ovarian cancer, cancer antigen 125 [CA-125] value can assist in diagnosis.
- Ovarian cancer is diagnosed with histologic confirmation in all settings.
- CT-guided biopsy or laparoscopy (with sufficient resources) is preferred instead of laparotomy to obtain histologic confirmation prior to any systemic therapy.

See Table 5 and Appendix Figures A1 and A7.*

Clinical question B.

What is the optimal surgery for women with stages I-IV EOC (including fallopian tube and primary peritoneal cancer)?

- The purpose of surgery is to diagnose, to stage, and/or for treatment.
- Ovarian cancer surgery should be performed by trained gynecologic oncologists or surgeons with oncology surgical expertise. Refer patients to highest-resourced level oncology center with oncology surgical capacity.
- Staging: Where feasible, patients with presumed early-stage ovarian cancer should undergo surgical staging by trained surgeon(s). In basic settings, surgical staging is not feasible, thus not recommended.
- Treatment: Women with advanced ovarian cancer (stage III and IV) should receive optimal surgical debulking to remove all visible disease to improve overall survival (OS) by trained surgeon(s).

See Tables 5 and 6 and Appendix Figures A2, A8, and A9.*

General statement about chemotherapy: Access to appropriate evidence-based chemotherapy agents, contraindications to chemotherapy, and potential side effects of chemotherapy should be evaluated and managed in every patient. Basic-resource

(continued on following page)
THE BOTTOM LINE (CONTINUED)

settings that most likely lack the capacity to provide safe administration of chemotherapy should refer patients to a higher-level center for evaluation. Limited settings without skilled capacity should refer patients to settings with access to specialized care.

Clinical question C.
What is the optimal adjuvant and/or systemic therapy for stages I-IV EOC (including fallopian tube and primary peritoneal cancer)?

- Clinicians should document pathology and stage to determine eligibility for adjuvant chemotherapy. If pathology confirmation is not possible because of patient or resource limitation, alternatives can be discussed.
- Clinicians should not administer (systemic treatment) adjuvant chemotherapy to patients with ovarian low–malignant potential tumors or early-stage microinvasive borderline tumors, independent of stage.
- Combination chemotherapy with paclitaxel and carboplatin is the standard of care for adjuvant therapy in ovarian cancer.
- Single-agent carboplatin may be used because of resource limitation or patient characteristics.
- Only in enhanced settings, highly selected cases can be assessed for appropriate evidence-based intraperitoneal (IP) chemotherapy, following optimal debulking, where there are resources and expertise to manage toxicities.

See Table 7 and Appendix Figures A3, A4, and A10.*

Clinical question D.
What is the optimal treatment for women with recurrent EOC (including fallopian tube and primary peritoneal cancer)?

- For recurrent disease in limited or enhanced settings only, patients with recurrent ovarian cancer should be counseled on treatment options on the basis of a patient’s prior response to platinum-based chemotherapy, that is, platinum-sensitive, platinum-resistant, or platinum-refractory disease status. Platinum rechallenge is only recommended for patients with platinum-sensitive disease.
- In enhanced settings only, clinicians may offer maintenance systemic therapies.
- Treatment is not recommended for patients with tumor marker–positive (CA-125) only recurrent ovarian cancer.
- Early palliative care interventions benefit all patients diagnosed with ovarian cancer.
- See related ASCO guidelines in the Appendix.

See Table 7 and Appendix Figures A5, A6, and A10.*

General statement about heritable risk: For women with strong family history of breast and/or ovarian cancer, clinicians should discuss family history and refer to counseling or testing, if available.

Additional Resources
More information, including a supplement, slide sets, and clinical tools and resources, is available at www.asco.org/resource-stratified-guidelines. The Methodology Manual (available at www.asco.org/guideline-methodology) provides additional information about the methods used to develop this guideline. Patient information is available at www.cancer.net.

ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care and that all patients should have the opportunity to participate.

*Full list of recommendations and corresponding tables are available in the Data Supplement.
Diagnosis, Staging, and Treatment of Patients With Ovarian Cancer

Different regions of the world, both among and within countries, have variable access to diagnosis and treatment of EOC. Patients with cancer of the ovary ideally require the care of specialized surgical teams including gynecologic oncologists and general surgeons who have extensive training in oncology. However, outside of specialized centers within high-HDI regions, there is a paucity of specialty training with few clinicians available to skillfully manage these patients. Some of the presumptions inherent in the guideline include that chemotherapy and specialized surgery are not available in basic settings (Table 2). As a result of these disparities, the American Society of Clinical Oncology (ASCO) Resource-Stratified Guidelines Advisory Group chose epithelial cancer of the ovary as a priority topic for guideline development.

ASCO has established a process for development of resource-stratified guidelines, which includes mixed methods of evidence-based guideline development, adaptation of the clinical practice guidelines of other organizations, and formal expert consensus. This article summarizes the results of that process and presents resource-stratified recommendations (see Results section).

### TABLE 1. Incidence and Mortality of Ovarian Cancer

<table>
<thead>
<tr>
<th>HDI</th>
<th>No.</th>
<th>Crude Rate</th>
<th>ASR</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>313,959</td>
<td>8.1</td>
<td>6.6</td>
</tr>
<tr>
<td>Low</td>
<td>15,379</td>
<td>3.1</td>
<td>5.1</td>
</tr>
<tr>
<td>Medium</td>
<td>6,559,480,973</td>
<td>5.8</td>
<td>6.0</td>
</tr>
<tr>
<td>Combined low HDI, low income, low middle income, medium HDI</td>
<td>176,709</td>
<td>5.2</td>
<td>5.9</td>
</tr>
<tr>
<td>High</td>
<td>116,505</td>
<td>8.1</td>
<td>6.1</td>
</tr>
<tr>
<td>Very high</td>
<td>116,347</td>
<td>14.7</td>
<td>8.3</td>
</tr>
</tbody>
</table>

Incidence of ovarian cancer

Mortality of ovarian cancer

<table>
<thead>
<tr>
<th>HDI</th>
<th>No.</th>
<th>Crude Rate</th>
<th>ASR</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>207,252</td>
<td>5.4</td>
<td>4.2</td>
</tr>
<tr>
<td>Low</td>
<td>11,106</td>
<td>2.2</td>
<td>4.0</td>
</tr>
<tr>
<td>Medium</td>
<td>4,559,856,704</td>
<td>4.0</td>
<td>4.3</td>
</tr>
<tr>
<td>Combined low HDI, low income, low middle income, medium HDI</td>
<td>122,452</td>
<td>3.6</td>
<td>4.2</td>
</tr>
<tr>
<td>High</td>
<td>76,796</td>
<td>5.3</td>
<td>3.8</td>
</tr>
<tr>
<td>Very high</td>
<td>73,655</td>
<td>9.3</td>
<td>4.3</td>
</tr>
</tbody>
</table>

Abbreviations: ASR, age-standardized rate; HDI, Human Development Index.

### TABLE 2. Diagnosis/Staging/Treatment Capacities by Setting

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Basic</th>
<th>Limited</th>
<th>Enhanced</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imaging</td>
<td>X-ray and US and expertise for interpretation</td>
<td>X-ray/US/CT may be available in some regions</td>
<td>CT/MRI available</td>
</tr>
<tr>
<td>Surgery</td>
<td>General practitioner with basic surgical capacity (can include some ovarian mass diagnostic procedures—not hysterectomy)</td>
<td>General surgeon, general surgery facility with OR, Ob/Gyn—by default has some oncology skills</td>
<td>OR, ICU, most major surgeries available, subspecialized oncologists, including surgical oncologists/gynecologic oncologists</td>
</tr>
<tr>
<td>Chemotherapy</td>
<td>Presume not available (for purposes of guidelines)</td>
<td>Some chemotherapy available. Only first-line</td>
<td>More chemotherapy options available, targeted therapy may or may not be available. May be ≥ first-line available</td>
</tr>
<tr>
<td>Pathology</td>
<td>Sending pathology for review when needed may or may not be available</td>
<td>Pathology services in development, H&amp;E usually available, IHC and molecular tests are usually not available</td>
<td>Pathology services usually available and IHC and molecular tests may be available</td>
</tr>
<tr>
<td>Palliative care</td>
<td>Palliative care service is not available. Limited medications for pain may be available</td>
<td>Pain and symptom management available; palliative care service is in development</td>
<td>Palliative care specialty service not always available</td>
</tr>
</tbody>
</table>

Abbreviations: CT, computed tomography; H&E, hematoxylin and eosin stain; ICU, intensive care unit; IHC, immunohistochemistry; MRI, magnetic resonance imaging; Ob/Gyn, obstetrician/gynecologist; OR, operating room; US, ultrasound.
In developing resource-stratified guidelines, ASCO has adopted its framework from the four-tier resource setting approach (basic, limited, enhanced, and maximal; Table 3) developed by Breast Health Global Initiative and modifications to that framework on the basis of the Disease Control Priorities 3. The framework emphasizes that variations occur not only between but also within countries with disparities, for example, between rural and urban areas.

GUIDELINE QUESTIONS

This clinical practice guideline addresses the following four overarching clinical questions:

(A) What are the optimal diagnosis and staging strategies for adult women with ovarian masses and/or EOC (including fallopian tube and primary peritoneal cancer)?

(B) What is the optimal surgery for women with stages I-IV EOC (including fallopian tube and primary peritoneal cancer)?

(C) What is the optimal adjuvant and/or systemic therapy for stages I-IV EOC (including fallopian tube and primary peritoneal cancer)?

(D) What is the optimal therapy for women with recurrent EOC (including fallopian tube and primary peritoneal cancer)?

| TABLE 3. Framework of Resource Stratification |
| Setting | |
| Basic | Core resources or fundamental services that are absolutely necessary for any public health/primary health care system to function; basic-level services typically are applied in a single clinical interaction. Vaccination is feasible for highest-need populations |
| Limited | Second-tier resources or services that are intended to produce major improvements in outcome such as incidence and cost-effectiveness and are attainable with limited financial means and modest infrastructure; limited-level services may involve single or multiple interactions. Universal public health interventions feasible for greater percentage of population than primary target group |
| Enhanced | Third-tier resources or services that are optional but important; enhanced-level resources should produce further improvements in outcome and increase the number and quality of options and individual choice (perhaps ability to track patients and links to registries) |
| Maximal | May use high-resource settings’ guidelines |

Addendum: Data adapted. To be useful, maximal-level resources typically depend on the existence and functionality of all lower-level resources. Maximal-level recommendations are not included in this guideline.

METHODS

Guideline Development Process

This systematic review–based guideline product was developed by an multinational, multidisciplinary Expert Panel, which included a patient representative and ASCO guidelines staff member with health research methodology expertise (Appendix Table A2). The Expert Panel met via teleconference and corresponded through e-mail. On the basis of the consideration of the evidence, the authors were asked to contribute to the development of the guideline, provide critical review, and finalize the guideline recommendations. Members of the Expert Panel were responsible for reviewing and approving the penultimate version of the guideline, which was then circulated for external review and submitted to a peer-reviewed journal for editorial review and consideration for publication.

This guideline adaptation was also informed by the ADAPTE methodology and consensus methodology together as an alternative to de novo guideline development for this guideline. Adaptation of guidelines is considered by ASCO in selected circumstances when one or more quality guidelines from other organizations already exist on the same topic. The objective of the ADAPTE process is to take advantage of existing guidelines to enhance efficient production, reduce duplication, and promote the local uptake of quality guideline recommendations.

ASCO’s adaptation process begins with a literature search by ASCO guidelines staff, to identify candidate guidelines for adaptation. Adapted guideline manuscripts are reviewed and approved by the ASCO Clinical Practice Guidelines Committee (CPGC). The review includes two parts: methodologic review and content review. The methodologic review is completed by a member of the CPGC’s Methodology Subcommittee and/or by ASCO guidelines staff. The content review is completed by an Expert Panel (Appendix Table A2). All funding for the administration of the project was provided by ASCO. Further details of the methods used for the development of this guideline are reported in the ASCO Guidelines Methodology Manual (available at www.asco.org/guideline-methodology).

This guideline was partially informed by ASCO’s modified Delphi Formal Expert Consensus methodology, during which the Expert Panel was supplemented by additional experts recruited to rate their agreement with the drafted recommendations. The entire membership of experts is referred to as the Consensus Panel (a list of members is available in Appendix Table A3). In round 1, 20 experts (plus two who were on the Expert Panel) participated; in round 2, there were a total of 25 respondents (nine of whom were on the Expert Panel). The guideline recommendations were drafted, in part, using the Guidelines Into Decision Support methodology. The guideline recommendations were sent for an open comment period of 2 weeks allowing the public to review and comment on the recommendations.
after submitting a confidentiality agreement. These comments were taken into consideration while finalizing the guideline. All ASCO guidelines are ultimately reviewed and approved by the Expert Panel and the ASCO Clinical Practice Guideline Committee prior to publication.

Guideline Disclaimer
The clinical practice guidelines and other guidance published herein are provided by the ASCO to assist providers in clinical decision making. The information therein should not be relied upon as being complete or accurate, nor should it be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. With the rapid development of scientific knowledge, new evidence may emerge between the time information is developed and when it is published or read. The information is not continually updated and may not reflect the most recent evidence. The information addresses only the topics specifically identified therein and is not applicable to other interventions, diseases, or stages of diseases. This information does not mandate any particular course of medical care. Further, the information is not intended to substitute for the independent professional judgment of the treating provider, as the information does not account for individual variation among patients. Recommendations reflect high, moderate, or low confidence that the recommendation reflects the net effect of a given course of action. The use of words like “must,” “must not,” “should,” and “should not” indicate that a course of action is recommended or not recommended for either most or many patients, but there is latitude for the treating physician to select other courses of action in individual cases. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. ASCO provides this information on an “as is” basis, and makes no warranty, express or implied, regarding the information. ASCO specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions.

Guideline and Conflicts of Interest
The Expert Panel was assembled in accordance with ASCO’s Conflict of Interest Policy Implementation for Clinical Practice Guidelines (“Policy,” found at [http://www.ascopubs.org/rwc](http://www.ascopubs.org/rwc)). All members of the Expert Panel completed ASCO’s disclosure form, which requires disclosure of financial and other interests, including relationships with commercial entities that are reasonably likely to experience direct regulatory or commercial impact as a result of promulgation of the guideline. Categories for disclosure include employment; leadership; stock or other ownership; honoraria, consulting or advisory role; speaker’s bureau; research funding; patents, royalties, other intellectual property; expert testimony; travel, accommodations, expenses; and other relationships. In accordance with the Policy, the majority of the members of the Expert Panel did not disclose any relationships constituting a conflict under the Policy.

RESULTS
Literature Search
The recommendations were developed through a systematic review of high-quality published guidelines and clinical experience. A search for new evidence was conducted by ASCO guidelines staff to identify systematic review–based guidelines published between January 2012 and March 2019 in PubMed, Cochrane Systematic Reviews, US AHRQ database (the formerly extant) and US National Guideline Clearinghouse databases and complemented with searches of G-I-N International Guideline Library (see the Data Supplement for details on the search). The search was restricted to articles published in English, French, or Spanish. Guidelines were selected for inclusion in the systematic review on the basis of the following criteria:

- 1. addressed the diagnosis or treatment of ovarian masses and/or ovarian cancer,
- 2. developed by multidisciplinary content experts as part of a recognized organizational effort, and
- 3. published between 2012 and 2019 (later narrowed to 2014-2019 to capture more current information).

The Expert Panel suggested two additional guidelines for review. The Expert Panel later narrowed the date parameter to between January 2014 and December 2019 (with the addition of some Panel-suggested literature and ASCO guidelines published up to June 2020).

Articles were excluded from the systematic review if they were (1) meeting abstracts; (2) books, editorials, commentaries, letters, news articles, case reports, or narrative reviews; or (3) primary literature. After initial searches of primary literature, the panel leadership decided to primarily use guidelines to inform expert consensus. ASCO considered quality guidelines that either met the US National Guidelines Clearinghouse 2013 criteria as assessed by National Guideline Clearinghouse or met ASCO criteria for Appraisal of Guidelines for Research and Evaluation II (AGREE II) methodologic review. Searches for cost-effectiveness analyses were also conducted separately. A total of 156 titles of guidelines were found in the literature searches. The ASCO Expert Panel reviewed nine of the guidelines that met inclusion criteria, in-depth for their currency, content, and methodology. On the basis of content and methodology reviews, the Expert Panel chose six non-ASCO guidelines and three ASCO guidelines (Scottish Intercollegiate Guidelines Network [SIGN], Belgian Health Care Knowledge Centre [KCE], ASCO and Society of Gynecologic Oncology [SGO], Ontario
Health—Cancer Care Ontario [OH-CCO],16 Japan Society of Gynecologic Oncology [JSGO],17 British Gynaecological Cancer Society [BGCS],18 Irish National Clinical Effectiveness Committee [NCEC],19 and the 2020 ASCO guidelines20,21). These evidence-based guidelines were developed by eight health authorities and/or guideline developers (SIGN, KCE, ASCO, SGO, OH-CCO, JSGO, BGCS, and Irish NCEC; one was a joint ASCO and SGO guideline). Appendix Table A1 lists links to the guidelines. The Expert Panel used these guidelines, literature suggested by the Expert Panel, and clinical experience as guides. The Expert Panel formally vetted the included guidelines’ content and development methodology. The Data Supplement encompasses a detailed overview of the included guidelines, including information on the clinical questions, target populations, development methodology, and key evidence.

This ASCO guideline reinforces selected recommendations offered in the SIGN, Belgian KCE, ASCO and SGO, ASCO, OH-CCO, JSGO, BGCS, and Irish NCEC guidelines and acknowledges the effort put forth by the authors and aforementioned societies to produce evidence-based and/or consensus-based guidelines informing practitioners and institutions who provide care to patients with ovarian masses and/or ovarian cancer.

**SUMMARY OF ADAPTED GUIDELINES**

**Guidelines on Assessment of Ovarian Masses and Treatment of Patients Diagnosed With Epithelial Ovarian Cancer**

The Expert Panel identified clinical questions and/or categories within the adapted guidelines that would potentially match the ASCO clinical questions. All the guidelines were developed on the basis of patients in maximal settings; therefore, the Expert Panel had to review and adapt the recommendations for resource-constrained settings on the basis of experience in resource-constrained settings and then validate the recommendations by formal consensus.22 All the guideline developers used different methods. Most of the maximal setting guidelines had clinical questions or key questions, including the Belgian KCE, Irish NCEC, ASCO and SGO, all the ASCO guidelines, JSGO, OH-CCO, and SIGN guidelines; the BGCS guidelines did not explicitly label clinical questions. The target populations were all in maximal settings and included people with ovarian masses, suspected ovarian cancer, and/or patients with carcinoma of the ovary, fallopian tube carcinoma, and primary peritoneal carcinoma—primarily epithelial ovarian carcinoma and are coalesced for the purposes of this document as epithelial ovarian cancer (EOC). The Irish NCEC guideline’s target population is specifically people with ovarian masses/suspected ovarian cancer, and the ASCO Germline and Somatic Tumor Testing guideline20 focuses on women diagnosed with ovarian cancer (with one recommendation on first- or second-degree blood relatives of a patient with ovarian cancer with a known germ line pathogenic cancer alteration; however, that discussion is outside the scope of this resource-stratified guideline). Four of the guidelines included both diagnosis and treatment: including Belgian KCE, BGCS, ASCO and SGO, and JSGO guidelines. Three, including the ASCO guideline on poly (ADP-ribose) polymerase inhibitors (PARPi), OH-CCO guidelines (OH-CCO was specifically on patients with EOC recurrence), and JSGO guidelines, focused on treatment only. Since this ASCO resource-stratified guideline does not include patients with germ cell tumors, sections of adapted guidelines that targeted that population were not used. Specific clinical questions (if provided) and target populations of the adapted guidelines are listed in the Data Supplement.

At the time of the systematic searches for high-quality existing guidelines for this ASCO resource-stratified guideline, there were multiple existing guidelines from maximal settings (see the Data Supplement). Four of the non-ASCO guidelines and all the adapted ASCO guidelines (including the guideline of ASCO and SGO) used systematic review–based methods. Two of the guidelines found were not traditionally systematic review–based. The key evidence the guidelines used included systematic reviews, meta-analyses, nonsystematic literature reviews, existing guidelines, observational studies, and consensus. Most of the evidence regarded systemic therapy. In some areas regarding other interventions, the guidelines used observational data. Therefore, many recommendations in this ASCO guideline were informed by this variety of expert-reviewed data and then validated by Formal Consensus.

The outcomes or end points in most studies reviewed by the adapted guidelines included efficacy (including overall survival and progression-free survival [PFS]), quality of life (QoL), safety and/or adverse events, and in some cases, cost-effectiveness.

**RESULTS OF ASCO METHODOLOGIC REVIEW**

The methodologic review of the guidelines was completed by two ASCO guideline staff members for each guideline using the Rigour of Development subscale of the AGREE II instrument (with the exceptions of the guidelines that ASCO developed [neoadjuvant, testing, and PARPi]). The score for the Rigour of Development domain is calculated by summing the scores across individual items in the domain and standardizing the total score as a proportion of the maximum possible score. Detailed results of the scoring and the AGREE II assessment process for this guideline are available in the Data Supplement.

**SELECTED RECOMMENDATIONS**

The recommendations were developed by a multinational, multidisciplinary group of experts using evidence from existing guidelines and clinical experience as a guide. The ASCO Expert Panel underscores that health care practitioners who implement the recommendations presented in this guideline should first identify the available resources in
their local and referral facilities and endeavor to provide the highest level of care possible with those resources. The authors would like to make some general points applying to recommendations throughout this guideline: outcomes should be balanced with QoL including financial toxicity; recommendations are made regarding what is feasible in resource-constrained settings.

Because of the large breadth of recommendations, the Panel elected to discuss selected areas.

**OVERARCHING CLINICAL QUESTION A**

What are the optimal diagnosis and staging strategies for adult women with ovarian masses and/or EOC?

**Evaluation and diagnosis of adult women with ovarian masses or symptoms of EOC (Recommendations 1.1-1.4)**

Recommendations on evaluation and diagnosis for women with ovarian masses are provided in Tables 5 and 6 and Appendix Figures A1, A2, A8, and A9. These recommendations are adapted, and in some cases modified from the guidelines from the developers Belgian KCE, Irish NCEC, SIGN, BGCS, and ASCO and SGO and informed by clinical expertise.

**Diagnostic Strategies**

**Discussion.** These recommendations concern assessment for adult women with ovarian masses in basic, limited, and enhanced settings.

**Basic-resource settings.** Women with ovarian cancer may report generalized symptoms of pain, fatigue, loss of appetite, abdominal bloating, or feeling full with small meals or early satiety. Other focal signs can include a patient’s report of a mass noted in the abdomen or symptoms of abdominal distension, abdominal or pelvic pain, and change in bowel function with diarrhea or constipation (for the latter, symptoms of < 12 months duration and occurring more than 12 times per month). Women presenting with symptoms associated with possible EOC require an evaluation. The cause of underlying symptoms, generally nonspecific but potentially severe or life-impacting in nature, needs to be determined and may lead to a potential cancer diagnosis. A general practitioner in a basic-resource setting has to rely on the patient’s history and physical examination findings to determine the need for diagnostic testing. Initial assessment by a general practitioner includes a complete physical examination, focusing on the abdominal and pelvic examination, to determine the presence of any pelvic or ovarian mass. A clinical diagnosis of ovarian cancer can be discussed on the basis of certain complements of symptoms. A symptom index has been validated and may be helpful in guiding care. Measuring the serum CA-125 tumor marker alone is not validated for diagnostic use; however, if more than 300 IU/mL, can be suggestive of serous ovarian cancer. CA-125 is less useful for women who are premenopausal, with early-stage ovarian cancer, with ovarian cancer of other epithelial types, or with non-epithelial ovarian tumors.

**Imaging**

Women who are postmenopausal with recurrent and persistent symptoms, even in the setting of a negative physical examination, require further evaluation with pelvic ultrasound (transabdominal and transvaginal ultrasound) and referral to a higher-level center for further evaluation including a CT scan. Upon completion of the history and physical examination, where resources allow, ultrasound-based imaging including a pelvic ultrasound is a general first step in the diagnostic evaluation.

The diagnostic evaluation for an ovarian mass is most widely performed with a pelvic ultrasound. Prospective studies from the International Ovarian Tumor Analysis group have identified 10 characteristics of benign versus malignant ovarian mass that are highly accurate and reproducible for diagnosis of ovarian cancer (Table 4). Evaluation of these features via pelvic ultrasound with the designation of benign, malignant, or inconclusive, in addition to clinical assessment, provides a general practitioner guidance for a referral to treatment.

A mass is classified as probable malignant if at least one malignant feature and none of the benign features are present or vice versa. If no benign or malignant features are present or if both benign and malignant features are present, then the rules are considered inconclusive (unclassifiable mass), and clinicians should use further clinical and diagnostic testing.

The clinical presentation and imaging findings of both benign (eg, peritoneal tuberculosis) and other malignancies (eg, GI cancer) may be similar or mimic those of ovarian cancer. Patients in basic-resource settings, when feasible, should be referred to a higher-level care center with capacity for surgical and medical management of patients when there is a concern for malignancy, either of ovarian or other types. Consequently, a histopathologic diagnosis should be undertaken prior to definitive treatment, with referral for diagnosis if feasible. Histology or cytology diagnosis of EOC should be made by a certified pathologist. See the Special Commentary on pathology for further details.

(Sources: SIGN, BGCS, Irish NCEC)

**Limited-resource settings.** Clinicians should perform the recommendations from the basic setting and may add CT if available. CT imaging of the abdomen and pelvis to include the lower lung fields, using oral and intravenous (IV) contrast where available, can help document the extent of disease spread to solid organ structures such as the liver, detail the severity of peritoneal carcinomatosis, rule out pleural effusion, and aid clinicians in surgical treatment planning (see recommendation 1.4 and recommendations 2.1.1-2.2.3). In women with respiratory symptoms, CT of
TABLE 4. International Ovarian Tumor Analysis Simple Rules

<table>
<thead>
<tr>
<th>Benign Features</th>
<th>Malignant Features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unilocular tumor (B1)</td>
<td>Irregular solid tumor (M1)</td>
</tr>
<tr>
<td>Largest diameter of largest solid component &lt; 7 mm (B2)</td>
<td>Ascites (M2)</td>
</tr>
<tr>
<td>Acoustic shadows (B3)</td>
<td>At least four papillary projections (M3)</td>
</tr>
<tr>
<td>Smooth multilocular tumor with largest diameter &lt; 100 mm (B4)</td>
<td>Irregular multilocular solid tumor with largest diameter ≥ 100 mm (M4)</td>
</tr>
<tr>
<td>No intratumoral blood flow at color or power Doppler (B5)</td>
<td>Very strong intratumoral blood flow at color or power Doppler (M5)</td>
</tr>
</tbody>
</table>

NOTE. Irish National Clinical Effectiveness Committee; Belgian Health Care Knowledge Centre (p 23).

the thorax provides a more complete evaluation, although this guideline does not recommend routinely performing it for all patients with suspected ovarian cancer in limited-resource settings. A chest x-ray is more accessible and cost-effective for evaluation of the thorax.

(Sources: SIGN, ASCO/SGO, Irish NCEC)

Enhanced-resource settings. In addition to recommendations from the basic and limited settings, magnetic resonance imaging provides a minimal added benefit to the assessment of an ovarian mass suspicious for diagnosis of ovarian cancer. CT imaging of the abdomen, pelvis, and thorax provides a more comprehensive evaluation of disease burden and is also beneficial in surgical treatment planning. Specific benign ovarian pathology such as fibroid disease or dermoid cyst(s) are optimally visualized with ultrasound and thus magnetic resonance imaging of the pelvis can be used only if the clinician’s decision making will be altered on the basis of radiologic findings.

(Sources: SIGN, ASCO/SGO, Irish NCEC)

Assessing heritable risk (Recommendation 1.3)

Discussion. This guideline is not focused on screening and/or genetic tests (the prespecified population in this guideline does not include asymptomatic individuals; ASCO has a maximal setting guideline for testing for women with a personal history of ovarian cancer but acknowledges that there is no global resource to inform what is available, accessible, and paid for by population-level care in each country and/or region). Assessing heritable risk of ovarian cancer is a part of diagnosis, but the overall population for this umbrella group of recommendations is women with ovarian masses, independent of potential individual heritable risk, and does not include populations that are asymptomatic. During the diagnosis for women with ovarian masses, the guideline stresses that the most important risk-related intervention is taking family history and related counseling, in all settings, recognizing that genetic counseling is not accessible to most women outside of maximal-resource settings. A 2015 ASCO policy statement “affirms that the recognition and management of individuals at inherited risk for cancer is a core element of oncology practice. The skills required to provide cancer risk assessment services are not specific to a discipline but rather incorporate elements from oncology, medical genetics and genetic counseling, and other disciplines. ASCO recommends continued education of oncologists and other health care professionals in the area of cancer risk assessment and management of individuals with an inherited predisposition to cancer.”

Family history includes the patient's age, cancer history, childbearing status and preferences, and that of close relatives (especially first- and second-degree relatives). First-degree relatives include a patient’s mother, father, sister, brother, daughter, or son; second-degree relatives are the first-degree relative(s) of a patient's first-degree relatives (grandparents, grandchildren, parent(s') siblings and their children, and half-siblings). Recommendations on genetic testing and how to best manage results are still equivocal in both resource-rich and resource-constrained settings.

Basic-resource settings. Clinicians evaluating women for ovarian masses in basic-resource settings should obtain a comprehensive family cancer history. Recognizing the heritable risk of ovarian cancer, family history of ovarian cancer are key supportive data to guide diagnosis. Families of women with a diagnosis of ovarian cancer seeking genetic counseling should be referred to a higher-level center with clinicians trained in cancer risk management.

Limited-resource and enhanced-resource settings. Clinicians should be mindful that to offer genetic testing, actionable next steps should be available, for example, follow-up counseling and genetic marker–based treatment(s). Guidelines serving as this resource-stratified guideline’s evidence base, for example, SIGN, state with a low level of evidence that screening for ovarian cancer in high-risk groups without confirmed diagnosis of personal or family history of cancer should only be offered in the context of a research study.

For additional reading, refer to evidence-based guidelines that explore the harms and benefits of BRCA testing and other genetic testing for individuals and populations at high risk, see Appendix Table A4.

(Source: informal consensus on the basis of Expert Panel opinion)

Minimally invasive techniques (Recommendation 1.4)

Discussion. Patients should be referred from basic or limited settings to higher-resourced settings wherever
OVERARCHING CLINICAL QUESTION B

What is the optimal surgery for women with stages I-IV EOC?

Staging for suspected stage I/II ovarian cancer (Recommendation 2.1.1)

Recommendations on staging are in Table 5, Appendix Figures A2 and A8, and the Data Supplement.

Discussion. Surgery is an essential element in ovarian cancer diagnosis and initial care, necessary for accurate diagnosis of ovarian cancer. Surgical staging follows or coincides with diagnostic interventions. Invasive intervention in patients with ovarian cancer is done for three reasons: tissue pathology diagnosis, surgical staging, or tumor debulking with the goal to achieve optimal tumor cytoreduction to R0 (no gross visible disease). In apparent early-stage ovarian cancer (stage I/II), appropriate surgical management of the ovarian mass includes minimizing risk of rupture. Surgical staging in apparent early-stage ovarian cancer provides prognostic information through comprehensive staging, if available. Complete staging helps to define prognosis and may change treatment course if a patient’s disease is unexpectedly upstaged and should ideally be undertaken by a subspecialized gynecologic oncology surgeon with appropriate experience or, where limitations exist, a gynecologist or general surgeon experienced in pelvic surgery. Surgery is performed to stage and remove all visible tumors; this may involve more than one surgical procedure or more than one surgical specialist to accomplish. Because of the complexity of ovarian cancer surgery and perioperative management of patients with ovarian cancer, patients should be referred to the highest-level care center with the capacity for expert surgical and medical management.

Surgical staging involves assessment and biopsies of the pelvis and abdomen, en bloc resection of the fallopian tubes, ovaries, uterus (see the Data Supplement for options in fertility-sparing surgery), infracolic omentectomy, evaluation of the bowel serosa and peritoneal surfaces from infradiaphragmatic space to the floor of the pelvis, pericolic gutter washings, and evaluation of the inferior aspect of the diaphragm. Systematic pelvic and para-aortic lymph node dissection is controversial and is only recommended when it will upstage and change the management of a patient’s early-stage disease.26

Basic-resource settings. In the absence of capacity to perform staging, patients should be referred to the next level of care. Where that is not possible, immediate symptom control and referral for subsequent care (surgery and/or chemotherapy) should be initiated.

TABLE 5. Summary Diagnosis Recommendations by Setting

<table>
<thead>
<tr>
<th>Disease Entity and/or Point of Service</th>
<th>Intervention [strength of recommendation]</th>
<th>B/L/E Setting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms</td>
<td>Clinical assessment [S]</td>
<td>B/L/E</td>
</tr>
<tr>
<td>Ultrasound (transabdominal ultrasound, pelvic ultrasound, and TUV), and interpret the results using the IOTA [S]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Family history [unrated]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CA-125 [M]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+Contrast-enhanced CT of abdomen and pelvis (with or without thorax) [S]</td>
<td>L/E</td>
<td></td>
</tr>
<tr>
<td>+MRI [W]</td>
<td></td>
<td>E</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>Family history [W]</td>
<td>All</td>
</tr>
<tr>
<td>Histologic confirmation for diagnosis (planning for NACT or not planning for NACT) [M]</td>
<td>L/E</td>
<td></td>
</tr>
<tr>
<td>Staging (suspected early stage v advanced stage)</td>
<td>Referral for staging surgery [W]</td>
<td>B/L</td>
</tr>
<tr>
<td>Metastatic workup [W]</td>
<td></td>
<td>L/E</td>
</tr>
<tr>
<td>Staging surgery [W]</td>
<td></td>
<td>E</td>
</tr>
</tbody>
</table>

Abbreviations: B, basic; CA-125, cancer antigen 125; CT, computed tomography; E, enhanced; IOTA, International Ovarian Tumor Analysis; L, limited; M, moderate; MRI, magnetic resonance imaging; NACT, neoadjuvant chemotherapy; S, strong; TUV, transvaginal ultrasound; W, weak.
**Limited-resource settings.** Diagnostic and surgical staging should proceed as in the Discussion, provided limited settings have appropriate surgical and postoperative expertise and pathology access. Lymph node dissection as part of comprehensive surgical staging for apparent early-stage ovarian cancer includes dissection of pelvic and para-aortic lymph nodes. Comprehensive surgical assessment for suspected stage I ovarian cancer provides the most accurate information for proper pathology-based staging, as this may affect recommendations for adjuvant chemotherapy options and ultimately survival.

Depending on the histologic grade and subtype, up to 30% of the patients with apparent early-stage ovarian cancer may be upstaged after pathology results of comprehensive surgical staging.

(Sources: SIGN/BGCS, Belgian KCE, BGCS Guidelines, JSGO Guideline)

**Enhanced-resource settings.** In addition to the recommendations in the basic and limited settings, positron emission tomography-CT is not validated as a diagnostic or staging tool for ovarian cancer.

(Sources: SIGN/BGCS, Belgian KCE, Irish NCEC)

**Fertility-sparing surgery and laparoscopic surgery for staging**

Recommendations on fertility-sparing surgery and laparoscopic surgery are in Table 6, Appendix Figures A2 and A8, and the Data Supplement.

**Fertility-sparing surgery (Recommendation 2.1.2)**

**Discussion.** A select subset of patients with stage I and low-grade ovarian cancer may qualify for fertility-sparing surgery. Where resources allow and in all resource settings, women who wish to preserve fertility options and with apparent early-stage ovarian cancer by imaging should be referred to the highest-level center for presurgery counseling and surgical management by a gynecology oncology surgical specialist. The goal of surgery is to preserve fertility options in addition to performing a comprehensive surgical staging to exclude micrometastasis. In limited-resource settings that lack access to frozen section pathology, a secondary surgery to complete standard procedure may be recommended after confirming final pathology. In the case of stage IB, the patient’s uterus can be preserved for future assisted-reproductive options. Women wishing to preserve fertility options should be counseled on the risks of recurrent ovarian cancer on the basis of histology and surgical stage.

Recommendation for fertility-sparing surgery options on the basis of histology:

- Borderline ovarian tumors (clear cell, serous, mucinous, or endometrioid) for stage IA, B, and C
- Mucinous carcinoma for stage IA, B, and C
- Low-grade endometrioid carcinoma for stage IA and B
- Low-grade serous carcinoma for stage IA and B
- Clear cell carcinoma—not recommended for any stage
- High-grade serous or endometrioid tumors—not recommended for any stage

**Limited-resource settings and enhanced-resource settings.** When young women are affected by early-stage EOC (low-grade), clinicians can offer fertility-sparing surgery following thorough discussion with the patient about the potential harm of recurrent ovarian cancer.

**Laparoscopic surgery for staging (Recommendation 2.1.3)**

**Discussion.** The preferred approach to surgical staging of suspected ovarian cancer is via a midline vertical incision; data have not yet been provided to validate the safety and equivalence of minimally invasive surgery (MIS) for newly diagnosed EOC care in any resourced setting. The use of laparoscopy for surgical staging in patients with apparent early-stage ovarian cancer is not recommended for basic- or limited-resource settings because of the lack of access to expert laparoscopic oncology surgeon(s) and access to necessary equipment for advanced laparoscopy. The safe selection of patients for MIS requires surgical oncology experience beyond laparoscopy surgical techniques. In enhanced settings with capacity for frozen section pathology, MIS may be offered for apparent early-stage ovarian cancer. In such select cases, patients and surgeons must be prepared to convert to a laparotomy procedure if comprehensive surgical staging cannot be completed via MIS.

**Surgical debulking for patients diagnosed with stage III and IV ovarian cancer (Recommendation 2.2.1)**

Recommendations on surgical debulking for patients diagnosed with stage III and IV ovarian cancer are in Table 6 and Appendix Figures A2 and A9.

**Discussion.** The goal of surgical management of stage III and IV ovarian cancer is to perform optimal tumor cytoreduction, which is achieved by resecting all visible tumor to < 1 cm and ideally to no visible tumor (R0). There is evidence that leaving residual disease > 1 cm is associated with a reduced chance of cure and negatively affects survival. As the benefit of surgery is diminished with suboptimal cytoreduction, all patients benefit from a multidisciplinary team (MDT) approach to their cancer care. A skilled surgeon should use clinical and radiologic examinations to determine the appropriateness of surgical intervention on the basis of patient and tumor factors with the intent to achieve complete surgical debulking with limited morbidity. Because of the inherent complexity of ovarian cancer surgery, surgeons skilled in oncologic surgery or trained gynecologic oncologists are best positioned to surgically manage patients with stage III or IV ovarian cancer. Decisions to perform surgery for these patients should take into account the health facilities’
capacity to provide safe perioperative care for patients with ovarian cancer because of the underlying risks associated with radical upper abdominal or multiorgan resections, large ascites, pleural effusion, nutritional needs, and patients’ preoperative reduced performance status (PS). PS is defined as “A measure of how well a patient is able to perform ordinary tasks and carry out daily activities.”

The extent of surgery to achieve complete cytoreduction may include bowel resection, upper abdominal exploration, and tumor debulking, or diaphragm resection and is best managed by oncology specialists and at facilities with resources to manage complex postoperative care including pain management. Decisions on bowel resection must consider potential cultural and resource limitations including management of long-term side effects. Routine pelvic and para-aortic lymphadenectomy in surgical management of advanced ovarian cancer (stage III/IV) is not indicated. Clinically enlarged lymph nodes should be removed as part of debulking procedure. As the surgical decision process for patients’ stage III and IV ovarian cancer is complex, this group of patients achieve the best disease outcome when managed by a gynecologic oncologist in the setting of a cancer center and should be referred to the highest-level cancer center for optimal cancer management.

**Basic-resource settings.** Because of a lack of resources at this level, the Expert Panel recommends that patients

### TABLE 6. Summary Treatment Recommendations by Setting

<table>
<thead>
<tr>
<th>Recommendation No.</th>
<th>Population</th>
<th>ASCO Resource Levels (B)</th>
<th>ASCO Resource Levels (L)</th>
<th>ASCO Resource Levels (E)</th>
<th>Strength of Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1.1</td>
<td>Low-risk* suspected stage I/II</td>
<td>Referral to L/E and/or resection if feasible</td>
<td>Referral to L/E and/or resection if feasible</td>
<td>Fertility-sparing surgery if suspected unilateral stage I OR refer to higher-level cancer center and/or resection</td>
<td>Weak</td>
</tr>
<tr>
<td>2.1.2</td>
<td></td>
<td></td>
<td></td>
<td>Fertility-sparing surgery if unilateral stage I. If not, staging and debulking resection</td>
<td></td>
</tr>
<tr>
<td>3.1.1</td>
<td>High-risk (stage I/III)</td>
<td>No chemotherapy</td>
<td>Combination adjuvant chemotherapy</td>
<td>Combination adjuvant chemotherapy</td>
<td>Moderate/strong</td>
</tr>
<tr>
<td>3.1.3</td>
<td></td>
<td></td>
<td></td>
<td>May assess patients with stage III for appropriate evidence-based targeted therapy, all patients with high-risk features and PS 0-2</td>
<td>Moderate/strong</td>
</tr>
<tr>
<td>3.2.1</td>
<td></td>
<td></td>
<td></td>
<td>(adjuvant chemotherapy) Weak (targeted therapy)</td>
<td></td>
</tr>
<tr>
<td>3.2.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.2.2</td>
<td>Eligible for NACT*</td>
<td>NACT and interval debulking is not recommended in basic settings</td>
<td>NACT ≤ 4 cycles</td>
<td>NACT ≤ 4 cycles</td>
<td>Weak</td>
</tr>
<tr>
<td>2.2.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.2.3 A and B</td>
<td>Metastatic post-systemic treatment surgery (stage III/IV)</td>
<td>Interval debulking is not recommended in basic settings</td>
<td>(A) If OR or SD to chemotherapy, then interval cytoreductive debulking surgery</td>
<td>(A) If OR or SD to chemotherapy, then interval cytoreductive debulking surgery</td>
<td>Strong</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(B) If PD, alternative chemotherapy regimens, clinical trials, and/or discontinuation of active cancer therapy and initiation of end-of-life care</td>
<td></td>
</tr>
<tr>
<td>3.1.1</td>
<td>Received surgery (adjuvant setting)*</td>
<td>Referral to higher-level cancer center</td>
<td>If staged and pathologically confirmed (or alternative confirmation), then adjuvant combination chemotherapy</td>
<td>If staged and pathologically confirmed (or alternative confirmation), then adjuvant combination chemotherapy</td>
<td>Weak</td>
</tr>
<tr>
<td>3.1.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Moderate</td>
</tr>
<tr>
<td>3.3.5</td>
<td>Received surgery and prior chemotherapy (maintenance) (stage III/IV)</td>
<td>NA</td>
<td>NA</td>
<td>May discuss maintenance systemic therapies (eg, antiangiogenic, targeted therapy). For guidance regarding the use of PARPi, please refer to the ASCO guideline</td>
<td>Strong</td>
</tr>
</tbody>
</table>

**NOTE.** Table divided by modality: surgical for primary, surgical for metastatic, etc.

Abbreviations: B, basic; E, enhanced; FIGO, International Federation of Gynecology and Obstetrics; L, limited; NA, not applicable; NACT, neoadjuvant chemotherapy; OR, overall response; PARPi, poly (ADP-ribose) polymerase inhibitors; PD, progressive disease; PS, performance status; SD, stable disease.

*Exceptions: ovary appears abnormal and there is evidence of omental and/or peritoneal disease.

*Biopsy-proven FIGO stage IIIC or IV (specifically high tumor load/stage IVB), in expectantly high-morbidity surgery and patients with poor PS or unresectable disease.

*Except low-risk stage I.
requiring cytoreductive surgery be referred to higher levels of care.

**Limited-resource settings and enhanced-resource settings.** Complete cytoreductive surgery for patients with stage III or IV ovarian cancer should be performed by a gynecologic oncologist, general gynecologist, or general surgeon with experience in cancer surgery. Patients should be referred to the highest-level cancer center for optimal surgical management. Access to perioperative supportive services for complex surgical patients may be necessary to optimize surgical outcomes and minimize morbidity.

**Surgery after neoadjuvant chemotherapy (Recommendation 2.2.2-2.2.3)**

Recommendations on interval cytoreductive surgery after NACT are available in Table 6 and Appendix Figures A3 and A9.

**Discussion.** Patients with stage III/IV disease with bulky disease may benefit from NACT if a gynecologic oncologist or surgical oncologist reviews the case and deems the patient’s disease as unresectable or unlikely to achieve complete cytoreduction. Additional patients appropriate for NACT consideration include those with poor PS or at high surgical risk assessed by a surgical specialist. Research is underway on assessing response to NACT using validated scoring tools and nomograms, although reviewing this literature is outside this guideline’s scope.\(^{19}\) According to the ASCO and SGO guideline on NACT in stage IIIC and IV, only patients with response to chemotherapy or stable disease following three to four cycles of platinum-based chemotherapy benefit from interval cytoreductive surgery.\(^{15}\) The goal of surgery is the same as primary surgery to achieve optimal tumor cytoreduction to < 1 cm, ideally to no visible disease (R0). For patients whose tumor progresses during chemotherapy, interval surgery is not indicated as it offers no added survival benefit. Options for these patients include alternative chemotherapy regimens, clinical trials, and/or discontinuation of active cancer therapy and initiation of end-of-life care. In general, in the setting of progressive disease, there is little role for surgery, and it is not typically advised, unless for palliation (e.g., relief of bowel obstruction).

**Basic-resource settings.** This guideline recommends that patients at this level should be referred to higher levels of care, otherwise patients should be managed with supportive and palliative care interventions.

**Limited-resource settings.** Treatment response following NACT should be evaluated by an MDT and guided by imaging, tumor marker analysis, and physical examination. Response to NACT may be indicative of a greater likelihood of benefit from interval cytoreductive surgery. Patients with disease response or stable disease benefit from interval cytoreductive surgery to achieve tumor cytoreduction < 1 cm, ideally to no visible disease (R0) where feasible, otherwise achieve tumor cytoreduction to < 1 cm.

Options for patients with progressive disease with NACT are palliative systemic therapies, enrollment in clinical trials, single-agent therapies, or discontinuation of all therapies and pursuit of end-of-life care. There is a limited role for surgery in patients with poor response to chemotherapy. The decision for additional treatment in patients with progressive disease with NACT should be endorsed by the MDT, weighing the risks and benefits in patients with poor survival outcomes.

**Enhanced-resource settings.** The same recommendations apply as in limited settings, with added capacity for more aggressive cytoreductive procedures by experienced and specialized surgeons and/or gynecologic oncologists.

**OVERARCHING CLINICAL QUESTION C**

What is the optimal adjuvant and/or systemic therapy for stages I-IV EOC?

Recommendations on adjuvant and systemic therapy are in Appendix Figures A3 and A10 and Table 6.

**Adjuvant chemotherapy following surgery in patients with stage I EOC (Recommendations 3.1.1-3.1.5)**

**Discussion.** Stage I ovarian cancer is potentially curable; early and accurate treatment is fundamental to optimizing survival outcomes. Adjuvant chemotherapy may follow any attempt at best possible surgical staging and debulking. Clinicians should use information from surgical staging to guide adjuvant chemotherapy decisions and define disease prognosis. Since patients with previously presumed early-stage ovarian cancer may be upstaged,\(^{27,28}\) women who were previously deemed not likely to require adjuvant chemotherapy may qualify for adjuvant therapy given known benefit for OS.\(^{31}\) Patients with stage I ovarian cancer who are incompletely staged or completely staged with residual disease experience survival benefit from adjuvant chemotherapy. Adjuvant chemotherapy should not replace additional surgery where feasible.

The OS for stage I EOC is high, although a subset of women is at a higher risk of relapse. Adjuvant chemotherapy does not improve survival for women with stage I A or IB low-grade (grade 1) endometrioid, serous, or mucinous ovarian carcinoma. This subset of patients is classified as having low-risk early-stage EOC. The risk of relapse is increased with incompletely staged and any grade disease; clear cell, while not normally graded, is considered a high-grade, high-risk histology, and these subsets of patients benefit in improved OS with adjuvant chemotherapy. The international standard-of-care recommendation for adjuvant chemotherapy is a taxane plus platinum doublet on an every-three-weekly schedule (once every 3 weeks) for a total of six cycles; clinicians may use other platinum-based doublets, although there are no data showing noninferiority or superiority to platinum plus taxane doublets. Data exist on the use of three versus six cycles of treatment with nonsignificant difference in survival outcome, although six
cycles is recommended for stage I high-grade serous histology. Moderately well-differentiated or grade 2 disease can be reclassified as low-grade or high-grade by demonstration of p53 mutation by immunohistochemistry.\textsuperscript{32-34} In the absence of resources, ease can be reclassified as low-grade or high-grade by immunohistochemistry, and distant recurrence is recommended for stage I high-grade serous ovarian cancer, with the greatest benefit documented for those with no residual disease (R0) (see the SIGN guideline).\textsuperscript{12} Chemotherapy delivery with paclitaxel plus cisplatin is associated with increased side effects of renal toxicity, neuropathy, fatigue, abdominal discomfort, and infection, frequently leading to early discontinuation of the regimen and change to standard IV chemotherapy. Patients should be counseled about these complications and management options to mitigate side effects, including the need for placement of an IP catheter. IP chemotherapy can be offered in an enhanced setting, for select patients where expertise and supportive services exist to manage toxicities.

**Targeted therapy for patients with stage III and IV ovarian cancer (Recommendation 3.2.3 and 3.3.4)**

**Discussion.** This guideline is using the term targeted therapy for bevacizumab and PARPi for the management of EOC. The guideline presumes that these are not available in basic- and limited-resource settings.

A modest PFS benefit and no OS benefits were seen in both randomized phase III trials examining incorporation of the antiangiogenic vascular endothelial growth factor inhibitor, bevacizumab, to platinum-based doublets and continued in maintenance therapy.\textsuperscript{35,36} The subgroups for whom the greatest, albeit still modest, benefit was observed\textsuperscript{35,36} on the basis of data from two large randomized clinical trials, GOG 0218 and ICON-7, were in subsets of patients with ascites or bulky residual disease.\textsuperscript{35,37,38} Bevacizumab can be offered for patients with high risk of disease (stage IV and suboptimal tumor cytoreduction stage III).\textsuperscript{35} Bevacizumab use should be limited to settings with the capacity to closely monitor and manage its known toxicities including hypertension, GI perforation, arterial or venous thromboembolism, or bleeding.\textsuperscript{18} Use of PARPi is recommended only in more-resourced settings and should follow the ASCO guidelines for use of PARPi in ovarian cancer.\textsuperscript{21}

**Basic-resource settings.** Targeted therapy is not recommended in basic settings.

**Limited-resource settings.** Targeted therapy is not recommended in limited-resource settings because of issues of access and toxicity, including financial toxicity.

**Enhanced-resource settings.** For enhanced settings, bevacizumab is an option, where feasible for appropriately selected stage III/IV patients. Cost and safety concerns with the management of toxicities may limit applicability.

**Maintenance systemic therapy (Recommendation 3.3.5)**

Recommendations on maintenance systemic therapy for patients with stage III/IV ovarian cancer after adjuvant chemotherapy are available in Appendix Figure A4 and Table 6.

**Discussion.** The benefit of maintenance chemotherapy with antiangiogenic vascular endothelial growth factor inhibitor bevacizumab in all subgroups of patients is still under debate in the absence of strong data; see the Discussion under Recommendation 3.2.3.\textsuperscript{38} In patients with...
stage II to IV low-grade serous histology, maintenance hormonal therapy can be discussed; the data are limited, and there is no clearly documented OS benefit at the time of this writing. As new information continues to evolve, future updates of this and other ASCO guidelines will discuss other new agents including PARPi, following enough evidence of efficacy. The major limitation to maintenance therapy such as PARPi in resource-constrained settings is lack of access to biomarker testing, including identification of patients with homologous recombination repair deficiency (HRD) and, more specifically, patients with tumors exhibiting BRCA mutation. Where biomarker testing results indicate treatment, continuous access to medication and cost-effectiveness analysis specific to resource settings must be ensured.

**Limited-resource settings.** In limited-resource settings, maintenance therapy with antiangiogenic agents is not recommended because of cost limitations and clinician experience in toxicity management.

**Enhanced-resource settings.** In enhanced-resource settings, clinicians may discuss maintenance therapy with antiangiogenic agents with select patients (those with stage III/IV disease) and potentially PARPi (for latter, see ASCO PARPi guideline, *JCO*, 2020). Institutions that use maintenance treatment with antiangiogenic and/or PARPi agents need capacity for evaluation and management of side effects.

**OVERARCHING CLINICAL QUESTION D**

What is the optimal therapy for women with recurrent EOC? (see Table 7 and Appendix Figures A5, A6, and A10)

**Discussion**

Despite the initial success with first-line surgery and chemotherapy for ovarian cancer, most patients will develop recurrent disease. The risk of recurrence is highest with advanced and high-grade or clear cell disease. Recurrent ovarian cancer is stratified into platinum-sensitive or platinum-resistant on the basis of the length of time to relapse (≥ 6 months v < 6 months, respectively) from the end of treatment with first-line platinum-based chemotherapy. Chemotherapy is the primary intervention for recurrent disease; where chemotherapy is not feasible for any reason, palliative care, if not already invoked, should be initiated.

(Source: BCGS, OH-CCO, SIGN)

**Surgery for recurrent EOC (Recommendation 4.0)**

Recommendations on surgery for patients with recurrence are in Table 7.

### TABLE 7. Summary Treatment of Recurrent EOC Recommendations by Setting

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Population</th>
<th>ASCO Resource Levels (B)</th>
<th>ASCO Resource Levels (L)</th>
<th>ASCO Resource Levels (E)</th>
<th>Strength of Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.0</td>
<td>Recurrent small-volume platinum-sensitive disease EOC</td>
<td>Because of health system gaps, not feasible in the basic setting</td>
<td>Refer to higher-level cancer center for surgical consideration</td>
<td>Perform complete secondary cytoreductive debulking surgery</td>
<td>Moderate: L/E</td>
</tr>
<tr>
<td>4.1/4.4</td>
<td>Recurrent EOC who have received prior systemic treatment</td>
<td>Best supportive care</td>
<td>Early palliative care</td>
<td>Early palliative care</td>
<td>Strong</td>
</tr>
<tr>
<td>4.1/4.2</td>
<td>Recurrent platinum-sensitive, platinum-resistant, platinum-refractory EOC—who have received prior systemic treatment, PS 0-2</td>
<td>N/A</td>
<td>Treatment with second-line chemotherapy or refer to higher-level cancer center</td>
<td>Treatment with second-line chemotherapy</td>
<td>Moderate: L Strong: E</td>
</tr>
<tr>
<td>4.2</td>
<td>Platinum-sensitive EOC</td>
<td>N/A</td>
<td>Platinum-sensitive: combination chemotherapy with carboplatin</td>
<td>Platinum-sensitive: combination chemotherapy with carboplatin with or without bevacizumab</td>
<td>Strong: L/E</td>
</tr>
<tr>
<td></td>
<td>Platinum-resistant EOC</td>
<td>N/A</td>
<td>Single-agent nonplatinum chemotherapy or best supportive care</td>
<td>Single-agent nonplatinum chemotherapy with or without bevacizumab or best supportive care</td>
<td>Resistant Strong: L/E</td>
</tr>
<tr>
<td></td>
<td>Platinum-refractory EOC</td>
<td>N/A</td>
<td>Single-agent nonplatinum chemotherapy with or without biologic agent (bevacizumab)</td>
<td>Single-agent nonplatinum chemotherapy with or without biologic agent (bevacizumab)</td>
<td>Refractory Moderate: E</td>
</tr>
</tbody>
</table>

Abbreviations: B, basic; E, enhanced; EOC, epithelial ovarian cancer; L, limited; N/A, not available; PS, performance status.
Discussion

Limitations in access to advanced therapies in resource-constrained settings support the discussion of secondary cytoreductive surgery in select patients with recurrent ovarian cancer. General agreement is that this intervention should only be considered for women with platinum-sensitive, delayed tumor recurrence, limited disease, good underlying performance and end organ status, and access to optimal surgical and postoperative support. Prognostic factors associated with best surgical outcomes are isolated site(s) of tumor recurrence and limited ascites (<500 mL).

Secondary cytoreduction can be considered for appropriately selected patients. The research describing the potential benefit of secondary debulking surgery is ongoing; however, given the level of expertise with this procedure and the need of an MDT to proceed with this type of surgery, it should not be performed in a resource setting other than maximal.

Basic-resource settings

Patients with recurrent disease should be referred to a higher-level care center wherever possible and to palliative care if not already started. Although there is a limited role for secondary cytoreductive surgery in recurrent ovarian cancers, this may be the only therapeutic opportunity to ameliorate symptoms for women in basic-resource settings.

Limited-resource settings

In settings where systemic therapy is not readily available and a skilled general surgeon or gynecologist trained in appropriate skills in oncologic surgery is available, evaluation and surgical management for recurrent ovarian cancer can be considered as one approach to disease management. All patients should be evaluated by an MDT, if available, to avoid unnecessary and risky surgical intervention.

(Source: JSGO Guideline, BCGS, SIGN)

Enhanced-resource settings

The proper care for women with recurrent ovarian cancer, with the exception of very limited resource situations, is systemic therapy. Secondary cytoreductive surgery can be discussed for highly selected platinum-sensitive patients; survival benefit is limited to patients for whom clinicians can achieve complete cytoreductive surgery. For all other patients with ovarian cancer, surgery should be withheld, except for symptom management such as for limited bowel obstruction readily overcome with diversion.

(Source: BCGS)

Systemic and palliative treatment for recurrent EOC (Recommendations 4.1-4.4)

Recommendations on systemic treatment and palliative care for patients with recurrent ovarian cancer are in Table 7.

Discussion. Systemic therapy is the cornerstone of managing patients with recurrent disease. Approaches to recurrent disease will vary with resource availability to multiple chemotherapy agents, location and severity of recurrence, and prior treatment exposures. Recurrent disease is not amenable to cure but patients with platinum sensitivity have improved PFS and OS when re-treated with platinum-based single-agent or doublet therapy. Few if any opportunities may be available to women with recurrent disease in basic-resourced areas and palliative care may be the only option. Surgery is not recommended except in select patients who had complete resection at up-front surgery, long recurrence-free survival, and limited disease at re-presentation.25 Decisions for surgery in recurrent EOC must take into account patient risk factors, access to qualified surgical capacity, system-based resources, and access to second-line chemotherapy agents. Systemic chemotherapy and targeted therapy recommendations depend upon resource support and platinum-free interval (Table 8).

Cost, access, and safety issues with targeted therapies such as bevacizumab are of concern in limited and enhanced settings, although there may be benefits in management of ascites. Bowel perforation, thromboembolism, fatigue, and hypertension are grade 3 and 4 toxicities occurring in patients receiving bevacizumab and are of grave concern, especially in weaker health systems. Clinical trials and newer targeted agents may be available in some limited and enhanced settings. Patients should be referred to higher-resourced settings for these and other opportunities when eligible and feasible.

Patients in the platinum-resistant group do not derive benefit from platinum rechallenge. The current standard of

<table>
<thead>
<tr>
<th>TABLE 8. Risk-Stratified Groups</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Platinum-Sensitive</strong></td>
</tr>
<tr>
<td>Platinum-free interval</td>
</tr>
<tr>
<td>Patients with no prior platinum-based therapy are also in this group</td>
</tr>
</tbody>
</table>

NOTE. Platinum-sensitive if the platinum-free interval is 6 months or more; some guidelines have a partially sensitive group if the platinum-free interval is between 6 and 12 months. There are no approvals internationally that apply this definition (Ontario Health—Cancer Care Ontario).16
TABLE 9. Selected Limitations and Future Directions From Adapted Guidelines

<table>
<thead>
<tr>
<th>Item</th>
<th>Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Role of tumor histology</td>
<td>JSGO</td>
</tr>
<tr>
<td>MRI for staging</td>
<td>Irish NCEC</td>
</tr>
<tr>
<td>Maintenance, especially with novel agents</td>
<td>Multiple</td>
</tr>
<tr>
<td>Diagnostic accuracy of secondary tests, including reproducibility</td>
<td>Tests in secondary care to identify people at high risk of ovarian cancer. Diagnostics guidance [DG31]. Published date: November 15, 2017. URL: <a href="https://www.nice.org.uk/guidance/dg31/chapter/6-Recommendations-for-further-research">https://www.nice.org.uk/guidance/dg31/chapter/6-Recommendations-for-further-research</a>. Page last updated: NR. Accessed: June 22, 2020</td>
</tr>
<tr>
<td>Validating Chemotherapy Response Score and consequent risk stratification</td>
<td>ASCO/SGO</td>
</tr>
<tr>
<td>Use of (weekly) paclitaxel for NACT</td>
<td>ASCO/SGO</td>
</tr>
<tr>
<td>Novel agents in NACT</td>
<td>ASCO/SGO</td>
</tr>
<tr>
<td>Minimally invasive techniques</td>
<td>JSGO</td>
</tr>
<tr>
<td>Role of IP chemotherapy</td>
<td>Multiple</td>
</tr>
</tbody>
</table>

Abbreviations: IP, intraperitoneal; JSGO, Japan Society of Gynecologic Oncology; MRI, magnetic resonance imaging; NACT, neoadjuvant chemotherapy; NCEC, National Clinical Effectiveness Committee; NR, not reported; SGO, Society of Gynecologic Oncology.

care outside of a clinical trial is single-agent non–platinum-based chemotherapy with or without bevacizumab in maximal settings. An exception is the use of hormonal therapy for recurrent low-grade serous (and low-grade endometrioid) ovarian cancer, where the pathologic diagnosis and grade are confirmed. The platinum-refractory group has a poor prognosis with short disease-free intervals and should be managed with palliative intent (Table 7).

(Sources: BCGS, OH-CCO, JSGO, SIGN)

**Basic-resource settings.** Palliative care involvement, if not already initiated, should be the primary focus alone or along with referral to higher-resourced settings.

**Limited-resource settings.** Access to an MDT, systemic therapies, and oncology expertise is likely inconsistent in most limited-resource settings. Patients should be managed on the basis of platinum-free intervals, ability to tolerate additional chemotherapy, treatment and palliative support, and access to nonplatinum agents. Toxicity profiles of recommended therapies should be discussed with the patient including available options for management of toxicities.

**Enhanced-resource settings.** Recommendations for recurrent EOC outlined for limited-resource settings are applicable in the enhanced settings. When an MDT endorses targeted therapies, including antiangiogenic agents or PARPi (see ASCO guideline), a clinician may discuss these options with patients. The strength of the health system determines the feasibility of administering targeted agents. Outcomes should be balanced with QoL including financial toxicity. ASCO has developed new guidelines for the use of targeted therapies including PARPi in the management of ovarian cancer in maximal settings and these can be discussed in enhanced-resource settings where applicable.

**SPECIAL COMMENTARY**

**Pathology**

Pathology is an important part of diagnosing the type of EOC and guiding management of women with this disease. There is variable availability and financing for pathology services around the world. In some regions, clinicians may even have to make diagnoses without pathology. ASCO resource-stratified guidelines use the capacity framework in Table 2 to guide pathology recommendations. As resource-constrained regions develop pathology services, the Expert Panel would like to make some suggestions specific to ovarian cancer.

The clinical presentation and imaging findings of both benign (e.g., peritoneal tuberculosis) and other malignancies (e.g., GI cancer) may be similar or mimic those of ovarian cancer. Consequently, a histopathologic diagnosis should be undertaken prior to definitive treatment. Pathologic diagnosis may be rendered on a peritoneal or omental biopsy, particularly in patients for whom there is the potential for neoadjuvant intervention, or on resection specimens following laparotomy or laparoscopy. Usually, routine histologic processing of formalin-fixed tissue is sufficient for pathologic diagnosis. Immunohistochemical studies may provide additional confirmatory evidence, but are often not critical to diagnosis. Alternatively, a cytopathologic diagnosis may be enough if this specialized service...
is available. In some limited and enhanced settings, ascitic fluid can be sent to pathology for cell block in major cities. Where laboratories are of variable quality, cytology alone can be problematic. In some cases, immunohistochemical tests can be sent to a central laboratory to confirm diagnosis, especially if a sample is mucinous.

ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care and that all patients should have the opportunity to participate. The expansion of oncology clinical trials in limited and enhanced settings is a global oncology priority.

COST IMPLICATIONS
An ASCO literature search focusing on high-quality systematic reviews of published cost-effectiveness analyses in low-resource settings was conducted, and none were found.

LIMITATIONS OF THE RESEARCH AND FUTURE DIRECTIONS
There were limitations on the evidence to inform some of the recommendations because of many recognizable factors such as prioritization of patient care and limited funding and infrastructure for research. Limitations include insufficient research conducted in resource-constrained settings, lack of conclusive research on primary/prevention screening, lack of published data on ovarian cancer genetic risk evaluation, and management adapted to resource-constrained settings. Expert recommendations for resource-constrained settings should account for differential access to chemotherapy across basic- and limited-resource settings. A shortage in human resources of trained gynecologic oncologists has led to task-shifting with variation in skill set among general practitioners, obstetricians/gynecologists, general surgeons, and oncologists able to manage patients with ovarian cancer.

There is a significant need to further ovarian cancer research in resource-constrained settings, considering issues of surgery and chemotherapy access, treatment effectiveness, and cost-effectiveness. The paucity of ovarian cancer genetic research in limited-resource settings needs further investigation, which can be achieved through collaborative research. The use of targeted therapy in adjuvant, maintenance, and recurrent ovarian cancer is actively under investigation, and further guidelines will include updates. Further limitations are listed in Table 9.

EXTERNAL REVIEW AND OPEN COMMENT
The draft recommendations were released to the public for open comment from June 29 through July 13, 2020. Response categories of “Agree as written,” “Agree with suggested modifications,” and “Disagree. See comments” were captured for every proposed recommendation with 10 written comments received. A total of 90% of the 10 respondents either agreed or agreed with slight modifications to the recommendations and 10% of the respondents disagreed. Expert Panel members reviewed comments from all sources and determined whether to maintain original draft recommendations, revise with minor language changes, or consider major recommendation revisions. All changes were incorporated prior to CPGC review and approval.

The draft was submitted to six external reviewers with content expertise; two completed the reviews. It was rated as high quality, and it was agreed it would be useful in practice. Review comments were reviewed by the Expert Panel and integrated into the final manuscript before approval by the CPGC.

GUIDELINE IMPLEMENTATION
ASCO guidelines are developed for implementation across health settings. Barriers to implementation include the need to increase awareness of the guideline recommendations among frontline practitioners and patients with ovarian cancer and to provide adequate services in the face of limited resources. The guideline Bottom Line was designed to facilitate implementation of recommendations. This guideline will be distributed widely, including through many forms of ASCO communications and the ASCO website.

ADDITIONAL RESOURCES
Additional information including a supplement, evidence tables, and clinical tools and resources can be found at www.asco.org/resource-stratified-guidelines. Patient information is available there and at www.cancer.net.

RELATED ASCO GUIDELINES

Resource-Stratified Guidelines
- Palliative Care in the Global Setting40 (http://ascopubs.org/doi/10.1200/JGO.18.00026)
- Non–Resource-Stratified Guidelines
- Integration of Palliative Care into Standard Oncology Practice41 (http://ascopubs.org/doi/10.1200/JCO.2016.70.1474)
- Patient-Clinician Communication42 (http://ascopubs.org/doi/10.1200/JCO.2017.75.2311)
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by the authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/go/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Terence J. Colgan
Consulting or Advisory Role: LifeLabs
Research Funding: MT Pharma
Expert Testimony: J and J
Other Relationship: College of American Pathologists
Open Payments Link: https://openpaymentsdata.cms.gov/physician/xxxxxx/summary

Keichi Fujiwara
Honoraria: Kyowa Hakko Kirin, Zeria Pharmaceutical, Nippon Kayaku, Chugai Pharma, Eisai, Taiho Pharmaceutical, Daichi Sankyo, Ono Pharmaceutical, Takeda
Consulting or Advisory Role: AstraZeneca, MSD, Taiho Pharmaceutical, Eisai, Takeda, Genmab, AbbVie, Pfizer
Research Funding: Eisai, Kaken Pharmaceutical, Chugai Pharma, Shionogi, Immunogen, Oncotherapeutics, AstraZeneca, Lilly, Zeria Pharmaceutical, Ono Pharmaceutical, MSD, Genmab, Regeneron
Travel, Accommodations, Expenses: Pfizer, AbbVie, MSD

Asima Mukhopadhyay
Research Funding: Meda
Patents, Royalties, Other Intellectual Property: Royalty payment from Clovis Oncology for contribution toward development of rucaparib as a member of the Newcastle University drug development team

Icó Tóth
Honoraria: MSD, SYNLAB
Travel, Accommodations, Expenses: Roche Magyarszág Kft, Roche Diagnostic Kft Hungary
Other Relationship: AstraZeneca, Roche Magyarszág Kft, MSD, Roche, Roche Diagnostic Kft Hungary, SYNLAB Kft Hungary, Roche Pharma AG, GlaxoSmithKline

Rahel G. Ghebre
Stock and Other Ownership Interests: Gilead Sciences
No other potential conflicts of interest were reported.

ACKNOWLEDGMENT

The Expert Panel wishes to thank external reviewers Dr Nathalie McKenzie, Dr Rodney Rocconi, and Dr Hannah Simonds; CPGC reviewers Dr Raetasha Dabney and Dr Jamie Lee Lesnock; and the Clinical Practice Guidelines Committee for their thoughtful reviews and insightful comments on this guideline adaptation. The Expert Panel also thanks the Consensus Panel members for their review of the guideline recommendations.
REFERENCES


### FIG A1. Diagnosis recommendations by resource setting. “Because of current gaps in health system and human resource availability. CA-125, cancer antigen 125; CEA, carcinoembryonic antigen; CT, computed tomography; MRI, magnetic resonance imaging; NACT, neoadjuvant chemotherapy.
### FIG A2. Staging and surgery recommendations by resource level.

*Because of current gaps in health system and human resource availability. FIGO, International Federation of Gynecology and Obstetrics; FSA, functional status assessment; NACT, neoadjuvant chemotherapy; PS, performance status.*
### FIG A3. Adjuvant/systemic therapy recommendations by resource level.

*Clinicians should offer carboplatin plus paclitaxel (or single-agent carboplatin) once every 3 weeks for six cycles. CA-125, cancer antigen 125; LMP, low malignant potential; PARPi, poly (ADP-ribose) polymerase inhibitor; PS, performance status.
Maintenance systemic therapies (antiangiogenic, targeted therapies) are not recommended for patients who have received surgery and prior chemotherapy. For guidance regarding the use of PARPi, refer to the ASCO guideline.

**FIG A4.** Maintenance systemic therapy recommendations by resource level. PARPi, poly (ADP-ribose) polymerase inhibitor.
Surgery for recurrent epithelial ovarian cancer

**Basic**
- Not feasible*
- Best supportive care

**Limited**
- For select patients with a small-volume platinum-sensitive recurrent disease, may refer to higher-level cancer center for surgical consideration
- Clinicians may recommend treatment with second-line chemotherapy to patients with platinum-sensitive and platinum-resistant/platinum-refractory ovarian cancer OR refer to higher-level cancer center
- Combination chemotherapy with carboplatin preferably for patients with platinum-sensitive recurrent ovarian cancer OR refer to higher-level cancer center
- Single-agent nonplatinum chemotherapy or best supportive care for patients with platinum-resistant/platinum-refractory recurrent ovarian cancer OR refer to higher-level cancer center
- No systemic treatment is recommended for tumor marker–positive (CA-125) only recurrent ovarian cancer in the absence of symptoms

**Enhanced**
- For select patients with a small-volume platinum-sensitive recurrent disease, may perform complete secondary cytoreductive debulking surgery
- Clinicians may recommend treatment with second-line chemotherapy to patients with platinum-sensitive and platinum-resistant/platinum-refractory ovarian cancer
- Combination chemotherapy with carboplatin preferably for patients with platinum-sensitive recurrent ovarian cancer
- Single-agent nonplatinum chemotherapy with biologic agent (bevacizumab) to patients with platinum-refractory ovarian cancer
- Limited setting recommendations

*Because of current gaps in health system and human resource availability. CA-125, cancer antigen 125.*

**FIG A5.** Recurrent ovarian cancer recommendations by resource level.
Clinicians should offer palliative care, including cancer pain and symptom management, to all patients diagnosed with ovarian cancer. Early referral to palliative care where available.

**FIG A6.** Palliative care recommendations by resource level.
Patients with symptoms of an ovarian mass

**Clinical assessment**

Combination of transabdominal, pelvic, and transvaginal ultrasound

Contrast-enhanced CT of abdomen and pelvis (with or without thorax)

Clinicians may add MRI

**Imaging**

Premenopausal

May use CA-125 to assist diagnosis

Should use CA-125 in evaluation

Should discuss family history and provide or refer to appropriate counseling

Should follow existing evidence-based guidelines for BRCA, if testing/follow-up available

May be a role for minimally invasive surgery such as laparoscopy for initial histologic diagnosis if planning for NACT for appropriate selected patients

When a biopsy cannot be performed, cytologic evaluation combined with a serum CA-125 to CEA ratio > 25 can confirm the primary diagnosis

Postmenopausal

**Biomarkers**

Assessing heritable risk

Histologic diagnosis

No role for minimally invasive techniques

**Patient category**

Basic

Limited

Enhanced

**Intervention category**

FIG A7. Diagnosis workup for patients with symptoms of an ovarian mass. *Because of current gaps in health system and human resource availability, CA-125, cancer antigen 125; CEA, carcinoembryonic antigen; CT, computed tomography; MRI, magnetic resonance imaging; NACT, neoadjuvant chemotherapy.
Patients with suspected stage I/II ovarian cancer

- Surgical staging
  - Patients with apparent stage I ovarian cancer should be referred to a higher-level care center with trained experts to perform appropriate surgical staging
  - Metastatic workup and referral for staging surgery
  - Metastatic workup and staging surgery
- Fertility-sparing surgery
  - No role for fertility-sparing surgery in early-stage disease
  - If sufficient expertise exists, may perform staging surgery
  - Elective minimally invasive laparoscopic surgery may be performed for select patients with apparent stage I ovarian cancer

**FIG A8.** Surgery for patients with suspected stage I/II ovarian cancer.
Patients with suspected stage III/IV ovarian cancer

Surgical evaluation

Evaluated for surgical management taking into account tumor burden, FSA, comorbidity

Counsel patients on treatment options and refer them to a cancer treatment center with specialized surgical services

Complete tumor cytoreduction to no gross residual disease/remove all macroscopic visible disease OR refer to higher-level cancer center

Complete tumor cytoreduction to no gross residual disease/remove all macroscopic visible disease

If unable to travel to a distant health center, refer to palliative care recommendations

NACT

Not feasible

NACT and interval debulking

Patients with progressive disease on NACT

Patients with a response to chemotherapy or stable disease

NACT and interval debulking OR refer to higher-level cancer center

If performed with curative intent, maximal effort cytoreductive surgery with the aim to remove all intra-abdominal macroscopic tumor

Basic

Limited

Enhanced

Patient category

Intervention category

TABLE A1. Adapted Guidelines and Links

<table>
<thead>
<tr>
<th>Developer</th>
<th>Title</th>
<th>URL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer Care Ontario, Toronto, ON, Program in Evidence-Based Care Guideline No.: 4-3v4. CCO PEBC4-3v4f, July 12, 2017, CCO,16</td>
<td>Systemic therapy for recurrent ovarian cancer</td>
<td><a href="https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/37871">https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/37871</a></td>
</tr>
<tr>
<td>ASCO20</td>
<td>Germline and somatic tumor testing in epithelial ovarian cancer</td>
<td><a href="https://www.asco.org/research-guidelines/quality-guidelines/guidelines/gynecologic-cancer#/142631">https://www.asco.org/research-guidelines/quality-guidelines/guidelines/gynecologic-cancer#/142631</a></td>
</tr>
<tr>
<td>ASCO21</td>
<td>PARP inhibitors in the management of ovarian cancer</td>
<td><a href="https://www.asco.org/research-guidelines/quality-guidelines/guidelines/gynecologic-cancer#/149680">https://www.asco.org/research-guidelines/quality-guidelines/guidelines/gynecologic-cancer#/149680</a></td>
</tr>
</tbody>
</table>

Abbreviations: BGCS, British Gynecological Cancer Society; CCO, Cancer Care Ontario; CPG, Clinical Practice Guideline; NACT, neoadjuvant chemotherapy; NCEC, National Clinical Effectiveness Committee; PARPi, poly (ADP-ribose) polymerase inhibitor; SGO, Society of Gynecologic Oncology; SIGN, Scottish Intercollegiate Guidelines Network.

FIG A10. Systemic therapy for patients with ovarian cancer (all stages). *Because of current gaps in health system and human resource availability. CA-125, cancer antigen 125; LMP, low malignant potential; PARPi, poly (ADP-ribose) polymerase inhibitor; PS, performance status.
<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation/Institution</th>
<th>Role/Area of Expertise</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jean Rene Clemenceau Valdivia, MD, Cochair (Writing Group member)</td>
<td>Hospital Angeles Del Pedregal, D.F., Mexico</td>
<td>Surgical oncology and medical oncology</td>
</tr>
<tr>
<td>Verna D. Vanderpuye, MD, Cochair (Writing Group member)</td>
<td>Korle Bu Teaching Hospital, Accra, Ghana</td>
<td>Radiation oncology</td>
</tr>
<tr>
<td>Rahel G. Ghebre, MD, MPH (Writing Group member)</td>
<td>University of Minnesota Medical School, Minneapolis, MN; St Paul’s Hospital Millennium Medical School, Addis Ababa, Ethiopia</td>
<td>Gynecologic oncology</td>
</tr>
<tr>
<td>Zeba Aziz, MD</td>
<td>Hameed Latif Hospital, Lahore, Pakistan</td>
<td>Medical oncology</td>
</tr>
<tr>
<td>William M. Burke, MD, SGO representative</td>
<td>Stony Brook University Hospital, Stony Brook, New York, NY</td>
<td>Gynecologic oncology</td>
</tr>
<tr>
<td>Nixon Leonardo Cevallos, MD</td>
<td>Sociedad Lucha Contra Cancer Ecuador, Machala, Ecuador</td>
<td>Medical oncology</td>
</tr>
<tr>
<td>Linus T. Chuang, MD</td>
<td>Nuvance Health System, Danbury, CT</td>
<td>Gynecologic oncology</td>
</tr>
<tr>
<td>Terence J. Colgan, MD, CAP representative</td>
<td>LifeLabs, Ontario, Canada</td>
<td>Pathology</td>
</tr>
<tr>
<td>Marcela G. del Carmen, MD, SGO representative</td>
<td>Massachusetts General Hospital, Boston, MA</td>
<td>Gynecologic oncology</td>
</tr>
<tr>
<td>Keiichi Fujiwara, MD, PhD</td>
<td>Saitama Medical University International Medical Center, Saitama, Japan</td>
<td>Surgical oncology</td>
</tr>
<tr>
<td>Jose Enrique Gonzales Nogales, MD</td>
<td>Instituto Nacional de Cancerologia, La Paz, Bolivia</td>
<td>Medical oncology</td>
</tr>
<tr>
<td>Thomas Okpoti Konney, MD</td>
<td>Komfo Anokye Teaching Hospital, Kumasi, Ghana</td>
<td>Gynecologic oncology</td>
</tr>
<tr>
<td>Asima Mukhopadhyay, MD, PhD, MSc</td>
<td>Chittaranjan National Cancer Institute, Kolkata, India; Northern Gynaecological Oncology Centre, Gateshead, Newcastle, United Kingdom</td>
<td>Surgical oncology</td>
</tr>
<tr>
<td>Bishnu D. Paudel, MD</td>
<td>NAMS, Bir Hospital, Kathmandu, Nepal</td>
<td>Medical oncology</td>
</tr>
<tr>
<td>Ic’o Tóth</td>
<td>Mallow Flower Foundation, Dunaharaszti, Hungary</td>
<td>Health advocacy</td>
</tr>
<tr>
<td>Sarikapan Wilailak, MD</td>
<td>Ramathibodi Hospital, Mahidol University, Bangkok, Thailand</td>
<td>Gynecologic oncology</td>
</tr>
<tr>
<td>Sarah Temin, MSPH</td>
<td>American Society of Clinical Oncology, Alexandria, VA</td>
<td>ASCO Practice Guideline Staff (health research methods)</td>
</tr>
</tbody>
</table>

Abbreviations: CAP, College of American Pathology; SGO, Society of Gynecologic Oncology.
### TABLE A3. Assessment of Ovarian Masses and Treatment of Epithelial Ovarian Cancer: ASCO Resource-Stratified Guideline Consensus Panel Membership

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ahmed Elzawawy</td>
<td>ICEDOC, SEMCO, AORTIC, and Harvard GHC Win-Win Initiative, Egypt</td>
</tr>
<tr>
<td>Alex Mutombo Baleka</td>
<td>Kinshasa University Hospital, DRC</td>
</tr>
<tr>
<td>David Cibula</td>
<td>Charles University and General Faculty Hospital, Czech Republic</td>
</tr>
<tr>
<td>Dennis Chi</td>
<td>Memorial Sloan Kettering Cancer Center, United States</td>
</tr>
<tr>
<td>Dorothy C. Lombe</td>
<td>Cancer Diseases Hospital, Zambia</td>
</tr>
<tr>
<td>Gilberto Lopes</td>
<td>University of Miami, United States</td>
</tr>
<tr>
<td>Julie Ann Francis</td>
<td>Lakeridge Health, ON</td>
</tr>
<tr>
<td>Julie Gralow</td>
<td>University of Washington, United States</td>
</tr>
<tr>
<td>Lalit Kumar</td>
<td>All India Institute of Medical Sciences, India</td>
</tr>
<tr>
<td>Maria Del Pilar Estevez-Diz</td>
<td>Instituto do Câncer do Estado de São Paulo, Brazil</td>
</tr>
<tr>
<td>Marwan Ghosn</td>
<td>Faculty of Medicine, Saint Joseph University, Beirut, Lebanon</td>
</tr>
<tr>
<td>Monica Malik</td>
<td>Nizam’s Institute of Medical Sciences, India</td>
</tr>
<tr>
<td>Nicoleta Antone</td>
<td>Oncology Institute Prof Dr I. Chiricuta, Romania</td>
</tr>
<tr>
<td>Olutosin A. Awolude</td>
<td>College of Medicine, University of Ibadan/University College Hospital, Nigeria</td>
</tr>
<tr>
<td>Rakesh Chopra</td>
<td>CK Birla Hospital, Delhi, India</td>
</tr>
<tr>
<td>Robert L. Coleman</td>
<td>MD Anderson, United States</td>
</tr>
<tr>
<td>Roselle De Guzman</td>
<td>Manila Central University-FDTMF Hospital, Philippines</td>
</tr>
<tr>
<td>Tanja Fehm</td>
<td>University of Duesseldorf, Germany</td>
</tr>
</tbody>
</table>

NOTE. Disclosures of potential conflicts of interest provided by the consensus panel members are available in the guideline supplement.
TABLE A4. Brief Familial Risk Tools

<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Genetic testing guidelines/ASCO statements</td>
</tr>
<tr>
<td>USPSTF (screening) (BRCA) 2019</td>
</tr>
<tr>
<td>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. These NCCN Guidelines are currently available as Version 1.2020, December 14, 2019. nccn.org</td>
</tr>
<tr>
<td>ASCO—policy statement</td>
</tr>
<tr>
<td>ESMO</td>
</tr>
<tr>
<td>ACOG</td>
</tr>
<tr>
<td>SGO</td>
</tr>
</tbody>
</table>

Abbreviations: ACOG, American College of Obstetricians and Gynecologists; ESMO, European Society for Medical Oncology; NCCN, National Comprehensive Cancer Network; SGO, Society of Gynecologic Oncology; USPSTF, US Preventive Services Task Force.